Cerebrovascular Reactivity Impairment in Preclinical Alzheimer's Disease

Mohammed Alwatban, Daniel L. Murman, Greg Bashford

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND AND PURPOSE: A substantial overlap exists between declines in cerebral vasoreactivity (CVR) and symptomatic Alzheimer's disease (AD). CVR can be quantified using transcranial Doppler (TCD) measurement of cerebral blood flow velocities (CBFV) in the middle cerebral artery (MCA) with CO2 as a vasodilatory stimulus. The breath-hold acceleration index (BHAI) is a new, more reliable measure of CVR developed recently in our laboratory. Our primary goal is to explore the possibility of using TCD for asymptomatic AD screening. METHODS: A pilot study population was divided into three groups: 9 healthy control subjects, 8 subjects identified as preclinical AD, and 10 patients diagnosed with prodromal or mild AD. Control subjects had a Clinical Dementia Rating (CDR) score of 0 without elevated amyloid-β (Aβ) on amyloid positron emission tomography (PET) imaging, preclinical AD subjects had CDR = 0 with elevated Aβ, and prodromal to mild AD subjects had CDR scores ≥.5 and elevated Aβ. CVR was calculated using two indices: the conventional breath-holding index (BHI) and the new BHAI. TCD parameters between the three groups were compared. RESULTS: BHAI was able to distinguish between 9 normal control subjects and 8 preclinical-AD subjects with high statistical significance (P <.001). BHI and pulsatility index were able only to distinguish AD from healthy and preclinical subjects (P <.001). CONCLUSIONS: In this exploratory pilot study, CVR was significantly decreased in preclinical, prodromal, and mild AD subjects as compared to the healthy group. Lower CVR in the preclinical AD group was detected using the new BHAI index but not the conventional BHI index.

Original languageEnglish (US)
Pages (from-to)493-498
Number of pages6
JournalJournal of Neuroimaging
Volume29
Issue number4
DOIs
StatePublished - Jul 1 2019

Fingerprint

Alzheimer Disease
Breath Holding
Dementia
Amyloid
Cerebrovascular Circulation
Healthy Volunteers
Asymptomatic Diseases
Blood Flow Velocity
Middle Cerebral Artery
Positron-Emission Tomography
Population

Keywords

  • breath-holding index
  • cerebrovascular reactivity
  • preclinical Alzheimer's diseases
  • transcranial Doppler ultrasound

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Clinical Neurology

Cite this

Cerebrovascular Reactivity Impairment in Preclinical Alzheimer's Disease. / Alwatban, Mohammed; Murman, Daniel L.; Bashford, Greg.

In: Journal of Neuroimaging, Vol. 29, No. 4, 01.07.2019, p. 493-498.

Research output: Contribution to journalArticle

@article{87a1e3493b4f48d9a55c995a43607f72,
title = "Cerebrovascular Reactivity Impairment in Preclinical Alzheimer's Disease",
abstract = "BACKGROUND AND PURPOSE: A substantial overlap exists between declines in cerebral vasoreactivity (CVR) and symptomatic Alzheimer's disease (AD). CVR can be quantified using transcranial Doppler (TCD) measurement of cerebral blood flow velocities (CBFV) in the middle cerebral artery (MCA) with CO2 as a vasodilatory stimulus. The breath-hold acceleration index (BHAI) is a new, more reliable measure of CVR developed recently in our laboratory. Our primary goal is to explore the possibility of using TCD for asymptomatic AD screening. METHODS: A pilot study population was divided into three groups: 9 healthy control subjects, 8 subjects identified as preclinical AD, and 10 patients diagnosed with prodromal or mild AD. Control subjects had a Clinical Dementia Rating (CDR) score of 0 without elevated amyloid-β (Aβ) on amyloid positron emission tomography (PET) imaging, preclinical AD subjects had CDR = 0 with elevated Aβ, and prodromal to mild AD subjects had CDR scores ≥.5 and elevated Aβ. CVR was calculated using two indices: the conventional breath-holding index (BHI) and the new BHAI. TCD parameters between the three groups were compared. RESULTS: BHAI was able to distinguish between 9 normal control subjects and 8 preclinical-AD subjects with high statistical significance (P <.001). BHI and pulsatility index were able only to distinguish AD from healthy and preclinical subjects (P <.001). CONCLUSIONS: In this exploratory pilot study, CVR was significantly decreased in preclinical, prodromal, and mild AD subjects as compared to the healthy group. Lower CVR in the preclinical AD group was detected using the new BHAI index but not the conventional BHI index.",
keywords = "breath-holding index, cerebrovascular reactivity, preclinical Alzheimer's diseases, transcranial Doppler ultrasound",
author = "Mohammed Alwatban and Murman, {Daniel L.} and Greg Bashford",
year = "2019",
month = "7",
day = "1",
doi = "10.1111/jon.12606",
language = "English (US)",
volume = "29",
pages = "493--498",
journal = "Journal of Neuroimaging",
issn = "1051-2284",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Cerebrovascular Reactivity Impairment in Preclinical Alzheimer's Disease

AU - Alwatban, Mohammed

AU - Murman, Daniel L.

AU - Bashford, Greg

PY - 2019/7/1

Y1 - 2019/7/1

N2 - BACKGROUND AND PURPOSE: A substantial overlap exists between declines in cerebral vasoreactivity (CVR) and symptomatic Alzheimer's disease (AD). CVR can be quantified using transcranial Doppler (TCD) measurement of cerebral blood flow velocities (CBFV) in the middle cerebral artery (MCA) with CO2 as a vasodilatory stimulus. The breath-hold acceleration index (BHAI) is a new, more reliable measure of CVR developed recently in our laboratory. Our primary goal is to explore the possibility of using TCD for asymptomatic AD screening. METHODS: A pilot study population was divided into three groups: 9 healthy control subjects, 8 subjects identified as preclinical AD, and 10 patients diagnosed with prodromal or mild AD. Control subjects had a Clinical Dementia Rating (CDR) score of 0 without elevated amyloid-β (Aβ) on amyloid positron emission tomography (PET) imaging, preclinical AD subjects had CDR = 0 with elevated Aβ, and prodromal to mild AD subjects had CDR scores ≥.5 and elevated Aβ. CVR was calculated using two indices: the conventional breath-holding index (BHI) and the new BHAI. TCD parameters between the three groups were compared. RESULTS: BHAI was able to distinguish between 9 normal control subjects and 8 preclinical-AD subjects with high statistical significance (P <.001). BHI and pulsatility index were able only to distinguish AD from healthy and preclinical subjects (P <.001). CONCLUSIONS: In this exploratory pilot study, CVR was significantly decreased in preclinical, prodromal, and mild AD subjects as compared to the healthy group. Lower CVR in the preclinical AD group was detected using the new BHAI index but not the conventional BHI index.

AB - BACKGROUND AND PURPOSE: A substantial overlap exists between declines in cerebral vasoreactivity (CVR) and symptomatic Alzheimer's disease (AD). CVR can be quantified using transcranial Doppler (TCD) measurement of cerebral blood flow velocities (CBFV) in the middle cerebral artery (MCA) with CO2 as a vasodilatory stimulus. The breath-hold acceleration index (BHAI) is a new, more reliable measure of CVR developed recently in our laboratory. Our primary goal is to explore the possibility of using TCD for asymptomatic AD screening. METHODS: A pilot study population was divided into three groups: 9 healthy control subjects, 8 subjects identified as preclinical AD, and 10 patients diagnosed with prodromal or mild AD. Control subjects had a Clinical Dementia Rating (CDR) score of 0 without elevated amyloid-β (Aβ) on amyloid positron emission tomography (PET) imaging, preclinical AD subjects had CDR = 0 with elevated Aβ, and prodromal to mild AD subjects had CDR scores ≥.5 and elevated Aβ. CVR was calculated using two indices: the conventional breath-holding index (BHI) and the new BHAI. TCD parameters between the three groups were compared. RESULTS: BHAI was able to distinguish between 9 normal control subjects and 8 preclinical-AD subjects with high statistical significance (P <.001). BHI and pulsatility index were able only to distinguish AD from healthy and preclinical subjects (P <.001). CONCLUSIONS: In this exploratory pilot study, CVR was significantly decreased in preclinical, prodromal, and mild AD subjects as compared to the healthy group. Lower CVR in the preclinical AD group was detected using the new BHAI index but not the conventional BHI index.

KW - breath-holding index

KW - cerebrovascular reactivity

KW - preclinical Alzheimer's diseases

KW - transcranial Doppler ultrasound

UR - http://www.scopus.com/inward/record.url?scp=85061453113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061453113&partnerID=8YFLogxK

U2 - 10.1111/jon.12606

DO - 10.1111/jon.12606

M3 - Article

C2 - 30748053

AN - SCOPUS:85061453113

VL - 29

SP - 493

EP - 498

JO - Journal of Neuroimaging

JF - Journal of Neuroimaging

SN - 1051-2284

IS - 4

ER -